Xenon Pharmaceuticals Inc. (NASDAQ:XENE) Receives Average Rating of "Moderate Buy" From Analysts
Xenon Pharmaceuticals Inc. (NASDAQ:XENE) Receives Average Rating of "Moderate Buy" From Analysts
Xenon Pharmaceuticals Inc. (NASDAQ:XENE – Get Rating) has received an average recommendation of "Moderate Buy" from the fourteen brokerages that are covering the company, MarketBeat.com reports. One research analyst has rated the stock with a sell rating and ten have assigned a buy rating to the company. The average twelve-month target price among analysts that have issued ratings on the stock in the last year is $50.56.
據MarketBeat.com報道,氙氣製藥公司(納斯達克代碼:XENE-GET評級)已經收到了覆蓋該公司的14家券商對該公司的平均推薦,即“適度買入”。一位研究分析師對該股的評級為賣出,十位分析師對該公司的評級為買入。在過去一年對該股進行評級的分析師中,12個月目標價的平均水平為50.56美元。
A number of equities analysts recently commented on XENE shares. JPMorgan Chase & Co. raised their target price on Xenon Pharmaceuticals from $52.00 to $54.00 in a report on Wednesday, January 4th. Wells Fargo & Company started coverage on Xenon Pharmaceuticals in a research note on Monday, November 28th. They issued an "overweight" rating and a $50.00 price target for the company. Royal Bank of Canada increased their price target on Xenon Pharmaceuticals from $46.00 to $49.00 and gave the stock an "outperform" rating in a research note on Tuesday, October 11th. Cowen started coverage on Xenon Pharmaceuticals in a research note on Monday, December 12th. They issued an "outperform" rating for the company. Finally, Cowen started coverage on Xenon Pharmaceuticals in a research note on Monday, December 12th. They issued an "outperform" rating for the company.
一些股票分析師最近對Xene的股票發表了評論。摩根大通在1月4日週三的一份報告中將Xenon PharmPharmticals的目標價從52.00美元上調至54.00美元。富國銀行公司在11月28日星期一的一份研究報告中開始報道氙氣製藥。他們對該公司的評級為“增持”,目標價為50美元。加拿大皇家銀行在10月11日(星期二)的一份研究報告中將Xenon PharmPharmticals的目標價從46.00美元上調至49.00美元,並給予該股“跑贏大盤”的評級。考恩於12月12日星期一在一份研究報告中開始報道氙氣製藥。他們對該公司的評級為“跑贏大盤”。最後,考恩在12月12日星期一的一份研究報告中開始報道氙氣製藥。他們對該公司的評級為“跑贏大盤”。
Xenon Pharmaceuticals Price Performance
氙氣藥品價格表現
NASDAQ XENE opened at $36.48 on Friday. Xenon Pharmaceuticals has a 1-year low of $24.60 and a 1-year high of $41.39. The business's fifty day moving average price is $36.90 and its 200-day moving average price is $36.36. The stock has a market capitalization of $2.28 billion, a price-to-earnings ratio of -17.88 and a beta of 1.36.
納斯達克Xene上週五開盤報36.48美元。氙氣製藥的一年低點為24.60美元,一年高位為41.39美元。該業務的50日移動均線價格為36.90美元,200日移動均線價格為36.36美元。該股市值22.8億美元,市盈率為-17.88,貝塔係數為1.36。
Insider Activity
內幕活動
In related news, Director Gary Patou sold 2,057 shares of Xenon Pharmaceuticals stock in a transaction dated Wednesday, November 23rd. The stock was sold at an average price of $34.33, for a total value of $70,616.81. Following the completion of the transaction, the director now owns 23,573 shares in the company, valued at $809,261.09. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. Company insiders own 6.06% of the company's stock.
在相關新聞中,董事加里·帕圖在一筆日期為11月23日(星期三)的交易中出售了2,057股氙氣製藥股票。這隻股票的平均售價為34.33美元,總價值為70616.81美元。交易完成後,董事現在擁有該公司23,573股,價值809,261.09美元。這筆交易是在提交給美國證券交易委員會的一份文件中披露的,該文件可在以下網址獲得此超鏈接。公司內部人士持有該公司6.06%的股份。
Institutional Inflows and Outflows
機構資金流入和流出
Several institutional investors and hedge funds have recently added to or reduced their stakes in the stock. Quantbot Technologies LP bought a new stake in Xenon Pharmaceuticals in the third quarter worth about $46,000. BNP Paribas Arbitrage SA lifted its stake in Xenon Pharmaceuticals by 1,567.5% in the first quarter. BNP Paribas Arbitrage SA now owns 1,334 shares of the biopharmaceutical company's stock worth $41,000 after purchasing an additional 1,254 shares during the last quarter. Advisors Asset Management Inc. bought a new stake in Xenon Pharmaceuticals in the first quarter worth about $66,000. Great West Life Assurance Co. Can bought a new stake in Xenon Pharmaceuticals in the third quarter worth about $86,000. Finally, UBS Group AG lifted its stake in Xenon Pharmaceuticals by 102.1% in the second quarter. UBS Group AG now owns 2,472 shares of the biopharmaceutical company's stock worth $76,000 after purchasing an additional 1,249 shares during the last quarter. Hedge funds and other institutional investors own 92.49% of the company's stock.
幾家機構投資者和對衝基金最近增持或減持了該股。Quantbot Technologies LP在第三季度購買了價值約4.6萬美元的Xenon PharmPharmticals新股份。法國巴黎銀行套利公司在第一季度增持了Xenon製藥公司1,567.5%的股份。法國巴黎銀行套利公司現在持有這家生物製藥公司1,334股股票,價值41,000美元,此前在上個季度又購買了1,254股。Advisors Asset Management Inc.在第一季度購買了價值約66,000美元的Xenon PharmPharmticals新股份。大西部人壽保險公司在第三季度購買了價值約8.6萬美元的Xenon PharmPharmticals新股份。最後,瑞銀集團在第二季度增持了102.1%的Xenon PharmPharmticals股份。瑞銀集團(UBS Group AG)現在持有這家生物製藥公司2,472股股票,價值76,000美元,此前在上個季度又購買了1,249股。對衝基金和其他機構投資者持有該公司92.49%的股票。
About Xenon Pharmaceuticals
關於氙氣製藥公司
(Get Rating)
(獲取評級)
Xenon Pharmaceuticals Inc, a clinical-stage biopharmaceutical company, engages in developing therapeutics to treat patients with neurological disorders in Canada. Its clinical development pipeline includes XEN496, A Kv7 potassium channel opener that is Phase III clinical trials for the treatment of KCNQ2 developmental and epilepsy encephalopathy; and XEN1101, A Kv7 potassium channel opener, which is in Phase II clinical trial for the treatment of epilepsy and other neurological disorders.
氙氣製藥公司是一家臨牀階段的生物製藥公司,在加拿大致力於開發治療神經疾病患者的療法。其臨牀開發流水線包括治療KCNQ2發育性和癲癇腦病的第三階段臨牀試驗KV7鉀通道開放劑XEN496和治療癲癇和其他神經疾病的第二階段臨牀試驗KV7鉀通道開放劑XEN1101。
See Also
另請參閲
- Get a free copy of the StockNews.com research report on Xenon Pharmaceuticals (XENE)
- MarketBeat Week in Review – 1/16 – 1/20
- Does Old Dominion Show That Trucking Is Hitting The Brakes?
- Nordstrom Puts Fear Of Markdowns Into Retail Sector
- Exxon Mobil Stock: Within Striking Distance Of Buy Point
- High-Dividend-Yielding BHP Sees China Driving '23 Growth
- 免費獲取StockNews.com上有關Xenon製藥的研究報告(Xene)
- 市場回顧周-1/16-1/20
- Old Dominion是否表明Trucking正在踩剎車?
- 諾德斯特龍對零售業降價的擔憂
- 埃克森美孚股票:在Buy Point附近
- 高股息率的必和必拓認為中國推動了23年的增長
Receive News & Ratings for Xenon Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Xenon Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
獲得《氙氣藥業日報》的新聞和評級-在下面輸入您的電子郵件地址,通過MarketBeat.com的免費每日電子郵件時事通訊接收對Xenon製藥和相關公司的最新新聞和分析師評級的每日簡要摘要。